Evaxion to Unveil Preclinical Data for AML Vaccine at EHA 2026
Event summary
- Evaxion will present preclinical data for EVX-04, an off-the-shelf AML vaccine, at EHA 2026 Congress on June 13, 2026.
- EVX-04 targets non-conventional endogenous retrovirus (ERV) tumor antigens, identified using Evaxion's AI-Immunology™ platform.
- Evaxion plans to submit a clinical trial application for EVX-04 in the second half of 2026.
- EVX-04 is designed as an off-the-shelf vaccine, preproduced for immediate administration after diagnosis.
The big picture
Evaxion's presentation at EHA 2026 highlights the growing intersection of AI and immunotherapy in oncology. The company's AI-Immunology™ platform aims to streamline the discovery of novel cancer targets, addressing the unmet needs in aggressive hematologic malignancies like AML. The off-the-shelf nature of EVX-04 could significantly reduce treatment delays, a critical factor in AML's poor prognosis. Success in this area could validate Evaxion's TechBio approach and attract further investment or partnerships.
What we're watching
- Clinical Progression
- Whether EVX-04's preclinical success translates into clinical trial approval and subsequent efficacy in human studies.
- Market Differentiation
- How EVX-04's off-the-shelf design positions it against personalized cancer vaccines in the competitive AML treatment landscape.
- Partnership Potential
- The pace at which Evaxion can secure collaborations or licensing deals for EVX-04, given the data presented at EHA 2026.
Related topics